🔎 Trials Near Me

Utama › Sarkoma Ewing › Wilayah Columbia

Kajian klinikal Sarkoma Ewing di Wilayah Columbia

6 kajian untuk Sarkoma Ewing sedang mencari peserta di lokasi di Wilayah Columbia.

Bandar di Wilayah Columbia

Teks kajian rasmi (Bahasa Inggeris)

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

  • Children's National Hospital, Washington D.C.
  • Childrens National Hospital, Washington D.C.
Mengambil pesertaFasa 1
Umur 1 hingga 23 · Semua jantina · Dikemas kini 13 Ogo 2026 · NCT07172958

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

  • Sibley Memorial Hospital, Washington D.C.
Mengambil peserta
Sehingga umur 39 · Semua jantina · Dikemas kini 13 Jul 2026 · NCT06796543

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

  • Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 19 Mei 2026 · NCT04901702

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

  • Children's National Hospital, Washington D.C.
Mengambil pesertaFasa 1/2
Umur 2 hingga 30 · Semua jantina · Dikemas kini 3 Feb 2026 · NCT05734066

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

  • Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 2
18 Months – 40 Years · Semua jantina · Dikemas kini 12 Ogo 2025 · NCT05135975

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.